ProteoNic 2G UNic(R) Technology Licensed by Ginkgo Bioworks for BARDA-Supported Consortium Advancing Monoclonal Antibody Manufacturing for Anti-Filovirus Therapies

ProteoNic BV, a leading provider of premium vector technology for biopharmaceutical and viral vector production, today announced that its proprietary 2G UNic(R) technology has been licensed by Ginkgo ...
Daily Graphic

2026 Budget through lens of communication, digital transformation

Ghana’s 2026 National Budget marks a strategic departure from the traditional balancing of expenditure and revenue ...

How 5G RedCap Is Powering the Next Wave of IoT

G RedCap delivers the reliable, energy-efficient connectivity needed to prevent downtime, power automation and help factories ...
Microwaves & RF

Seamless Connectivity Everywhere: How NTNs Will Transform 6G

D network architecture and the backbone of 6G NTNs. Opportunities and challenges with NTNs. Non-terrestrial networks (NTNs) ...
Live Science

Breakthrough 3D wiring architecture enables 10,000-qubit quantum processors

The novel 3D wiring architecture and chip fabrication method enable quantum processing units containing 10,000 qubits to fit ...

ProteoNic 2G UNic® Technology Licensed by Ginkgo Bioworks for BARDA-Supported Consortium Advancing Monoclonal Antibody Manufacturing for Anti-Filovirus Therapies

ProteoNic BV, a leading provider of premium vector technology for biopharmaceutical and viral vector production, today announced that its proprietary 2G UNic® technology has been licensed by Ginkgo ...